Key takeaways
- New York State CLEP certification (24 June 2026) is a laboratory permit for a lab-developed test, completing 50-state availability for Tutivia — not FDA approval or a new reimbursement decision.
- FY25 revenue rose to US$3.61m with Tutivia volumes up to 1,173 tests, but the audited accounts carry a material going-concern uncertainty and flag a need for further funding before end-2026.
- A June 2026 placing at 0.35p raised roughly £2.5m but issued around 46% of existing shares; the widely circulated “14 new scientific advisers” claim could not be verified.
The catalyst
On 24 June 2026, Verici Dx plc (AIM: VRCI) announced via RNS that it had received Clinical Laboratory Evaluation Program (CLEP) certification from the New York State Department of Health for its Tutivia kidney-transplant rejection test. The company said the approval completes its authorisation to provide laboratory testing services in all 50 US states and the District of Columbia, creating nationwide availability for Tutivia. New York operates one of the most demanding state laboratory-oversight regimes in the United States and had been the last significant jurisdiction outstanding.
It is important to be precise about what this is. The certification is a state-level laboratory permit for a laboratory-developed test (LDT). It is not a clearance or approval of the product by the US Food and Drug Administration, nor is it a new reimbursement or coverage decision. The company’s own wording, and chief executive Sara Barrington’s accompanying comment, framed the milestone in terms of the rigour of New York’s LDT evaluation and the ability to serve clinicians nationwide. The working headline circulating around this event also referenced “14 new scientific advisers”; that specific claim could not be verified in any RNS or company release, and this article does not rely on it.
Company overview and business model
Verici Dx is an early-commercial diagnostics company focused on the kidney-transplant pathway. Its lead marketed product, Tutivia, is a blood-based test that combines RNA transcriptomics with proprietary machine learning to generate a risk score for acute rejection in transplant recipients, and to help distinguish rejection from other causes of graft injury such as BK-virus nephropathy and ischaemia-reperfusion injury. A companion pre-transplant test, Clarava, aims to stratify a recipient’s risk of early rejection before surgery. A third programme, Protega, remains in development and has been positioned as a research-use-only launch.
The commercial model is that of a US reference laboratory offering LDTs, billing chiefly through Medicare and commercial payers on a per-test basis. Alongside its own testing services, Verici Dx has a licensing relationship with Thermo Fisher Scientific tied to a post-transplant rejection assessment collaboration, which contributed a milestone payment in the most recent financial year. The company is UK-incorporated and AIM-quoted, but its operations and revenues are overwhelmingly US-based and US-dollar denominated.
The latest development
The New York certification matters commercially because reference laboratories generally cannot bill for tests on specimens drawn from New York State residents without CLEP approval, so the gap had left a material portion of the US transplant population effectively out of reach. Closing it removes a structural barrier rather than adding a new revenue stream overnight. The practical benefit is that national transplant centres and networks operating across state lines can now standardise on Tutivia without carve-outs, which should support the company’s efforts to convert and deepen relationships with large multi-site centres.
Recent financial performance
For the year ended 31 December 2025, audited by Crowe UK LLP, Verici Dx reported total revenue of approximately US$3.61m, comprising roughly US$2.86m of Tutivia test sales and a US$0.75m Thermo Fisher licensing milestone. That represents meaningful top-line growth, driven by test volumes: the company said 1,173 Tutivia tests were ordered in 2025, up from 334 in 2024. The adjusted EBITDA loss was around US$6.18m and the loss after tax approximately US$6.93m, reflecting the cost of building a commercial laboratory and salesforce well ahead of scale. Momentum appeared to continue into 2026, with the company reporting first-quarter Tutivia volume growth of around 32% quarter-on-quarter and the addition of new ordering centres. Broker Singer Capital Markets characterised the FY25 results as in line with expectations.
Balance sheet, cash and funding
This remains a pre-profit business that consumes cash. Verici Dx reported cash and cash equivalents of about US$3.34m at 31 December 2025. Critically, the audited accounts carry a material uncertainty in relation to going concern, with the auditors noting that the group will require additional funding before the end of 2026. That statement should be read at face value: continued operation is dependent on raising further capital.
The company has already returned to the market in 2026. On 5 June 2026 it announced the result of a placing to raise gross proceeds of approximately £2.5m at 0.35 pence per share, issuing 700,000,000 new shares — equivalent to roughly 46% of the existing issued share capital — with a portion structured as EIS/VCT-qualifying, and admission to trading expected on 23 June 2026. A separate retail offer followed. The scale of dilution is significant, and the low absolute share price underlines the micro-cap, penny-share character of the equity.
Operational progress and strategy
Strategically, the emphasis is on land-and-expand within US transplant centres. The company has said it works with around 29 ordering centres that between them account for roughly 20% of annual US kidney transplants, with repeat centres increasing volumes and the largest accounts growing fastest. That pattern — deepening usage within existing accounts while adding new ones — is the core of the commercial thesis, because it points to clinical stickiness once a centre integrates the test into its monitoring protocols. The New York certification, the earlier CAP accreditation and CLIA compliance, and the addition of CPT codes together build the regulatory and billing scaffolding needed to scale that adoption nationally.
Market and sector context
The clinical rationale rests on the limitations of the current standard of care. Serum creatinine and biopsy remain central to transplant monitoring, but creatinine is a lagging, non-specific marker and biopsy is invasive. Non-invasive molecular tests that can flag rejection risk earlier address a genuine unmet need. Verici Dx competes in a field that includes established donor-derived cell-free DNA and gene-expression assays from larger US diagnostics players, so its differentiation — RNA-based signatures spanning the pre- and post-transplant journey — must translate into clinical guideline traction and payer support to win share. The addressable opportunity is meaningful: several thousand kidney transplants are performed in the United States each year, and recipients require lifelong monitoring, so a test embedded in routine surveillance protocols can generate repeat volumes per patient. That recurring-testing dynamic is central to why diagnostics investors are drawn to the transplant-monitoring niche, but it also means incumbents with entrenched clinician relationships and payer contracts are formidable competitors that a smaller entrant must displace or coexist with.
Potential growth catalysts
Near-term catalysts include continued quarter-on-quarter Tutivia volume growth now that the 50-state footprint is complete; broader commercial payer contracting to complement existing Medicare reimbursement (Tutivia secured Medicare coverage in 2025, reimbursed at US$2,650 per test); further data publications supporting clinical utility; progression of the Clarava pre-transplant opportunity; and any monetisation from the Protega programme or the Thermo Fisher collaboration. Evidence of operating leverage — revenue growth outpacing cost growth — would be the most meaningful signal.
Key risks
The risks are substantial and typical of early-commercial diagnostics micro-caps. The business is loss-making and funding-dependent, with an explicit going-concern material uncertainty; further capital raises are likely and could be highly dilutive, as the June placing demonstrated. Reimbursement risk is central: coverage and pricing can change, and commercial-payer adoption is not guaranteed. The evolving US regulatory environment for LDTs could raise compliance costs. The shares are illiquid, volatile and speculative, and revenue remains modest in absolute terms. Investors should also note the currency mismatch between US-dollar operations and sterling-quoted equity.
Outlook
The near-term picture is one of a company with improving commercial signals but a tight financial position. Completing national access for Tutivia is a genuine de-risking of the addressable market, and volume trends have been encouraging. Whether that translates into a sustainable business depends on the pace of adoption, payer breadth and, above all, the ability to fund the journey to cash breakeven without excessive further dilution.
Conclusion
The New York certification is a real and logical milestone: it removes the last major geographic constraint on Tutivia and reinforces a commercialisation story that has been gaining volume. But it is a laboratory permit, not a regulatory or reimbursement transformation, and it does not by itself resolve the going-concern question flagged in the audited accounts. For a speculative, illiquid AIM micro-cap that has just issued nearly half its share capital again, the central tension is clear — commercial momentum on one side, the funding clock on the other.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...